Publication not explained
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
Featured Image
Read the Original
This page is a summary of: Continuation of bevacizumab and addition of hormone therapy following weekly paclitaxel therapy in HER2-negative metastatic breast cancer, OncoTargets and Therapy, November 2014, Taylor & Francis,
DOI: 10.2147/ott.s70654.
You can read the full text:
Contributors
The following have contributed to this page
